AS101 [ammonium trichloro (dioxyethylene-O-O') tellurate] is a new syn
thetic compound previously described by us as having immunomodulating
properties and minimal toxicity. Clinical trials are currently in prog
ress with AS101 in AIDS and cancer patients. AS101 has recently been f
ound to have radioprotective effects on hemopoiesis in irradiated mice
when administered prior to irradiation. Since the early. progenitors,
spleen colony-forming units (CFU-S), are the critical cells needed fo
r the reconstitution of the hemopoietic system, the mechanisms of acti
on of AS101 were explored in this study by examining the compound's ef
fect on the recovery of CFU-S, its protective effect on endogenous CFU
-S and its effect on self-renewal of CFU-S. We also studied the effect
of AS101 on the induction of progenitor cells into the radioresistant
S-phase of the cell cycle. On days 1 and 5 after irradiation, the num
ber of CFU-S in the bone marrow and spleen of AS101-treated mice was s
ignificantly higher than that of PBS-injected mice. Nine days after su
blethal doses of irradiation, the number of endogenous spleen colonies
was highest in mice given AS101 every 24 hours or every other day for
1 week prior to irradiation. AS101 administered immediately after irr
adiation, however, also resulted in an increase in the endogenous CFU-
S. The higher number of CFU-S found in each 9-day endogenous spleen co
lony suggests increased self-renewal of CFU-S in AS101-treated mice. M
oreover, we found that AS101 induced a higher number of progenitor cel
ls in the S-phase of the cell cycle. These findings suggest that the r
adioprotection conferred by AS101 results from induction of progenitor
cells in DNA synthesis (S-phase) and from the enhanced stimulation of
CFU-S, not only toward proliferation but also toward CFU-S self-renew
al.